Regarding the clinical significance of SF3B1 mutations, early studies suggested that MDS with SF3B1 mutations were associated with a better prognosis and a lower likelihood to transform into AML compared with MDS free of SF3B1 mutations [48,49,50,51,52]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.